CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cardiff goes south again
The latest onvansertib data, and an abrupt CEO departure, spook investors.
Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
